Table 3.

Anticoagulation approach in relation to cancer primary site, treatment, and patient

Neoplasm primary site	Incidence (%)	Age (> 65) (%)	Gender (F) (%)	Metastases (%)	HTAs (%)	Anticoagulation duration [median (Q1–Q3)]
GI	37.1	63.9	36.1	83	97	6.6 (4.8–9.8)
Lung	22.7	57.6	21.2	71.9	96.7	4.6 (2.2–7.5)
Woman reproductive system	16.2	51.1	100	54.4	100	6.5 (4.5–11.6)
Breast	8.9	57.7	100	65.4	83.3	7.5 (3.1–11.8)
Urinary system	8.3	70.8	12.5	82.6	87.5	6.1 (4–10.9)
Head and neck	2.4	14.3	28.6	50	100	7.6 (6–14.1)
Other	4.5	53.9	7.7	69.2	84.6	8.1 (4–16.3)